N/A
Completed N=107
Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy
Arthritis, Psoriatic, Psoriasis
Source: ClinicalTrials.gov NCT00303186 ↗
Enrolled (actual)
107
Serious AEs
0.0%
Results posted
Jul 2012
Primary outcomePrimary: Mean Cost Per Participant Per Month at Month 12 — 1026.32; 970.14; 4.14; 13.60 Euro/participant-month
Summary
The purpose of this study is to conduct an economic analysis on the cost of conventional therapy as compared to biologic therapy and the direct/indirect costs of disease management in patients with refractory psoriatic arthritis (PsA). Primary outcomes are to qualify the economic burden of refractory PsA care. The secondary outcomes are to assess efficacy, safety, and cost effectiveness of different therapies.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Cost Per Participant Per Month at Month 12 |
1026.32; 970.14; 4.14; 13.60; 11.32; 27.11 | — |
| PRIMARY Mean Cost Per Participant Per Month at Month 60 |
986.34; 946.70; 16.97; 8.55; 2.58; 11.55 | — |
| PRIMARY Incremental Cost-effectiveness Ratio (ICER) |
39678.6 | — |
| SECONDARY Number of Participants With Assessment in Ankylosing Spondylitis (ASAS) 20 Response |
75; 37 | — |
| SECONDARY Number of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC) |
86; 38 | — |
| SECONDARY Psoriasis Area and Severity Index (PASI) |
5.04; 1.29; 2.08 | <0.0001 sig |
| SECONDARY Bath Ankylosing Spondylitis Functional Index (BASFI) |
43.37; 25.65; 22.46 | <0.0001 sig |
| SECONDARY Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) |
5.95; 3.23; 3.34 | <0.0001 sig |
| SECONDARY Bath Ankylosing Spondylitis Radiology Index (BASRI) |
— | — |
| SECONDARY Modified Schober's Test |
10.65; NA; 5.91 | 0.004 sig |
| SECONDARY Chest Expansion Measurement |
4.38; NA; 10.85 | 0.015 sig |
| SECONDARY Occiput-to-wall Distance |
7.02; NA; 6.24 | 0.676 |
| SECONDARY Maastricht Ankylosing Spondylitis Enthesis Score (MASES) |
3.65; 2.17; 1.43 | <0.0001 sig |
| SECONDARY Number of Swollen and Tender Joints |
7.60; 16.97; 1.26; 7.97; 0.96; 5.49 | <0.0001 sig |
| SECONDARY Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response |
62.6; 70.6 | — |
| SECONDARY Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response |
41.5; 43.1 | — |
| SECONDARY Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response |
19.8; 26.9 | — |
| SECONDARY Radiographic Score Based on Wassenberg |
13.58; 11.66; 28.29 | 0.330 |
| SECONDARY Patient Global Assessment (PtGA) of Disease Activity Score |
63.51; 32.07; 33.16 | <0.0001 sig |
| SECONDARY Physician Global Assessment (PGA) of Disease Activity |
60.15; 26.43; 23.00 | <0.0001 sig |
| SECONDARY Visual Analogue Scale for Pain (VAS-pain) |
62.83; 31.39; 31.92 | <0.0001 sig |
| SECONDARY Erythrocyte Sedimentation Rate (ESR) |
42.07; 16.36; 16.61 | <0.0001 sig |
| SECONDARY C-reactive Protein (CRP) |
59.41; 42.07; 2.30 | <0.0005 sig |
| SECONDARY Duration of Morning Stiffness |
— | — |
| SECONDARY Health Assessment Questionnaire (HAQ) |
1.14; 0.71; 0.65 | <0.0001 sig |
| SECONDARY Euro Quality of Life (EQ-5D)- Health State Profile Utility Score |
0.38; 0.63; 0.63 | <0.0001 sig |
| SECONDARY Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS) |
46.91; 66.76; 64.17 | <0.0001 sig |
| SECONDARY 36-Item Short-Form Health Survey (SF-36) |
31.88; 40.80; 40.44; 39.15; 40.77; 45.03 | <0.0001 sig |
Eligibility Criteria
Inclusion Criteria
- Eighteen years of age or older
- Inflammatory arthropathy associated with psoriasis meet the ACR criteria for PsA
- Patients with diagnosis of active and progressive PsA who have failure with conventional treatments
Exclusion Criteria
- Significant concurrent medical diseases including cancer or a history of cancer, uncontrolled congestive heart failure, myocardial infarctions within 12 months or other clinically significant cardiovascular diseases, immunodeficiency syndromes or concomitant infectious diseases.
Data sourced from ClinicalTrials.gov (NCT00303186). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.